entity

eliglustat

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about eliglustat: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

4Connections

0Hypotheses

2Analyses

4Outgoing

0Incoming

0Experiments

2Debates

No AI portrait yet

Outgoing (4)

Target	Relation	Type	Str
Glucosylceramide	inhibits	drug	0.90
glucosylceramide accumulation	prevents	phenotype	0.90
CNS	inhibits	phenotype	0.70
Parkinson's_disease	targets	disease	0.70

Incoming (0)

Source	Relation	Type	Str
No incoming edges

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (2)

Scientific analyses that reference this entity

What is the therapeutic window between GCS inhibition efficacy and systemic toxi

neurodegeneration | 2026-04-11 | 0 hypotheses

GBA-Synuclein Loop Therapeutics for PD

neurodegeneration | 2026-04-01 | 8 hypotheses Top: 0.525

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (2)

Multi-agent debates referencing this entity

The debate identified systemic toxicity as a major concern for glucosylceramide

closed · Rounds: 4 · Score: 0.50 · 2026-04-20

How to break the GBA-alpha-synuclein bidirectional loop for Parkinson's Disease

closed · Rounds: 4 · Score: 0.90 · 2026-04-06

Related Research

Hypotheses and analyses mentioning eliglustat in their description or question text

No additional research found